Acetylsalicylic acid exhibits anticlastogenic effects on cultured human lymphocytes exposed to doxorubicin

Mutation Research - Genetic Toxicology and Environmental Mutagenesis

Volumn 626, Issue 1-2, 2007, Pages 155-161

  Antunes, Lusânia Maria Greggi ^a,b   Bueno, Rafaela de Barros e Lima ^b   Dias, Francisca da Luz ^b   Bianchi, Maria de Lourdes Pires ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF TRIÂNGULO MINEIRO   (Brazil)

Author keywords

Acetylsalicylic acid; Anticlastogenicity; Antimutagenesis; Chromosome aberrations; Doxorubicin; Lymphocytes

Indexed keywords

ACETYLSALICYLIC ACID; CLASTOGEN; DOXORUBICIN; MELHORAL; RUBIDOX;

ADULT; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD SAMPLING; CELL PROTECTION; CHROMOSOME ABERRATION; CHROMOSOME DAMAGE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; FEMALE; HUMAN; HUMAN CELL; LYMPHOCYTE CULTURE; MALE; METAPHASE; MITOSIS INDEX; NORMAL HUMAN; PRIORITY JOURNAL; VOLUNTEER;

ANTIMUTAGENIC AGENTS; ASPIRIN; CELLS, CULTURED; CHROMOSOME ABERRATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; HUMANS; LYMPHOCYTES;

EID: 33845332996     PISSN: 13835718     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mrgentox.2006.09.009     Document Type: Article

References (35)

1. Surh Y. Molecular mechanisms of chemopreventive effects of selected dietary and medicinal phenolic substances. Mutat. Res. 428 (1999) 305-327
2. Antunes L.M.G., Pascoal L.M., Bianchi M.D.P., and Dias F.L. Evaluation of the clastogenicity and anticlastogenicity of the carotenoid bixin in human lymphocyte cultures. Mutat. Res. 585 (2005) 113-119
3. Hare L.G., Woodside J.V., and Young I.S. Dietary salicylates. J. Clin. Pathol. 56 (2003) 649-650
4. Peek Jr. R.M. Prevention of colorectal cancer through the use of COX-2 selective inhibitors. Cancer Chemother. Pharmacol. 54 (2004) S50-S56
5. Drew J.E., Arthut J.R., Farquharson A.J., Russell W.R., Morrice P.C., and Duthie G.G. Salicylic acid modulates oxidative stress and glutathione peroxidase activity in the rat colon. Biochem. Pharmacol. 70 (2005) 888-893
6. Baron J.A., and Sandler R.S. Non-steroidal anti-inflammatory drugs and cancer prevention. Annu. Rev. Med. 51 (2000) 511-523
7. Hsu C.S., and Li Y. Aspirin potently inhibits oxidative DNA strand breaks: implications for cancer chemoprevention. Biochem. Biophys. Res. Comm. 293 (2002) 705-709
8. Niikawa M., Nakamura T., and Nagase H. Suppressive effect of aspirin on chromosome aberrations induced by mitomycin C in mice. Biol. Pharm. Bull. 24 (2001) 964-966
9. Ajith T.A., Subin J.P., Jacob J., Sanjay P.S., and Babitha N.V. Antimutagenic and anti-oxidant activities of the non-steroidal anti-inflammatory drug celecoxib. Clin. Exp. Pharmacol. Physiol. 32 (2005) 888-893
10. Moorhead P.S., Nowell P.C., Mellman W.J., Batipps D.P., and Hungeford D.A. Chromosome preparations of leukocytes cultured from human peripheral blood. Exp. Cell Res. 20 (1960) 613-616
11. Antunes L.M.G., and Takahashi C.S. Protection and induction of chromosomal damage by Vitamin C in human lymphocytes cultures. Teratogen. Carcinogen. Mutagen. 19 (1999) 53-59
12. ISCN. In: Karger S. (Ed). International System for Human Cytogenetics Nomenclature, Report of the Standing Committee on Human Cytogenetics Nomenclature (1985), ISCN, Basel 66-69
13. Heng H.H.Q., Liu G., Bremer S., Ye K.J., Stevens J., and Ye C.J. Clonal and non-clonal chromosome aberrations and genome variation and aberration. Genome 49 (2006) 195-204
14. Karahalil B., Şardaş S., Kocabaş N.A., Alhayiroǧlu E., Karakaya A.E., and Civelek E. Chromosomal aberrations under basal conditions and after treatment with X-ray in human lymphocytes as related to the GSTM1 genotype. Mutat. Res. 515 (2002) 135-140
15. Zeiger E. Illusions of safety: antimutagens can be mutagens, and anticarcinogens can be carcinogens. Mutat. Res. 543 (2003) 191-194
16. Mauer I., Weinstein D., and Solomon H.M. Acetylsalicylic acid: no chromosome damage in human leukocytes. Science 169 (1970) 198-201
17. Jarvik L.F., and Fleiss J.L. Acetylsalicylic acid and chromosome damage. Science 171 (1971) 829-830
18. Oldham J.W., Preston R.F., and Paulson J.D. Mutagenicity testing of selected analgesics in Ames Salmonella strains. Appl. Toxicol. 6 (1986) 237-243
19. Dunn T.L., Gardiner R.A., Seymor G.L., and Lavin M.F. Genotoxicity of analgesic compounds assessed by an in vitro micronucleus assay. Mutat. Res. 189 (1987) 299-306
20. Muller L., Kasper P., and Madle S. Further investigations on the clastogenicity of paracetamol and acetylsalicylic acid in vitro. Mutat. Res. 263 (1991) 83-92
21. Giri A.K., Adhikari N., and Khan K.A. Comparative genotoxicity of six salicylic acid derivatives in bone marrow cells of mice. Mutat. Res. 370 (1996) 1-9
22. Arkhipchuk V.V., Goncharuk V.V., Chernykh V.P., Maloshtan L.N., and Gritsenko L.S. Use of a complex approach for assessment of metimazole sodium and acetylsalicylic acid toxicity, genotoxicity and cytotoxicity. J. Appl. Toxicol. 24 (2004) 401-407
23. Islaih M., Halstead B.W., Kadura I.A., Reid-Hubbard J.L., Flick F., Altizer J.L., Thom D.J., Monteith D.K., Newton R.K., and Watson D.E. Relationships between genomic, cell cycle, and mutagenic responses of TK6 cells exposed to DNA damaging chemicals. Mutat Res. 578 (2005) 100-116
24. Weiss R.B. The anthracyclines: will we ever find a better doxorubicin?. Semin. Oncol. 19 (1992) 670-686
25. Weijl N.I., Cleton F.J., and Osanto S. Free radicals and antioxidants in chemotherapy-induced toxicity. Cancer Treat. Rev. 23 (1997) 209-240
26. Gewirtz D.A. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem. Pharmacol. 57 (1999) 727-741
27. Minotti G., Menna P., Salvatorelli E., Cairo G., and Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev. 56 (2004) 185-229
28. Conklin K.A. Cancer chemotherapy and antioxidants. J. Nutr. 134 (2004) 3201-3204
29. Simpson C., Herr H., and Courtville K.A. Concurrent therapies that protect against doxorubicin-induced cardiomyopathy. Clin. J. Oncol. Nurs. 8 (2003) 497-501
30. Resende F.A., Barcala C.A.M.A., Faria M.C.S., Kato F.H., Cunha W.R., and Tavares D.C. Antimutagenicity of ursolic acid and oleanoic acid against doxorubicin-induced clastogenesis in Balb/c mice. Life Sci. 79 (2006) 1268-1273
31. Costa W.F., and Nepomuceno J.C. protective effects of a mixture of antioxidant vitamins and minerals on the genotoxicity of doxorubicin in somatic cells of Drosophila melanogaster. Environ. Mol. Mutagen. 47 (2006) 18-24
32. Dhawan A., Kayani M.A., Parry J.M., Parry E., and Anderson D. Aneugenic and clastogenic effects of doxorubicin in human lymphocytes. Mutagenesis 18 (2003) 487-490
33. Gülkaç M.D., Akpinar G., Üstün,F H., and Kanli A.O. Effects of Vitamin A on doxorubicin-induced chromosomal aberrations in bone marrow cells of rats. Mutagenesis 19 (2004) 231-236
34. Inchiosa M.A., and Smith C.M. Effects of ibuprofen on doxorubicin toxicity. Res. Comm. Chem. Pathol. Pharmacol. 67 (1990) 63-78
35. DeAtley S.M., Aksenov M.Y., Aksenova M.V., Harris B., Hadley R., Harper P.C., Carney J.M., and Butterfield D.A. Antioxidants protect against reactive oxygen species associated with adriamycin-treated cardiomyocytes. Cancer Lett. 136 (1999) 41-46